Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios

Transfusion

Volumn 55, Issue 6, 2015, Pages 1186-1194

  El Ekiaby, Magdy ^a   Moftah, Faten ^b   Goubran, Heidi ^b   van Drimmelen, Harry ^c   LaPerche, Syria ^d   Kleinman, Steve ^e   Busch, Michael ^f   Lelie, Nico ^g  

^a Shabrawishi Hospital   (Egypt)

^b National Blood Transfusion Center   (Egypt)

^c Biologicals Quality Control   (Netherlands)

^d Institut National de Transfusion d Sang   (France)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^g Lelie Research   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; BLOOD DONOR; CONCENTRATION (PARAMETERS); EGYPTIAN; ERYTHROCYTE TRANSFUSION; GENOTYPE; HEPATITIS C; POLYMERASE CHAIN REACTION; PROBABILITY; RNA ANALYSIS; RNA REPLICATION; VIREMIA; VIRION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84998644388     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13061     Document Type: Article

References (36)

1. Prati D. Transmission of hepatitis C virus by blood transfusion and other medical procedures: a global review. J Hepatol 2006;45:607-16.
2. Bresters D, Mauser-Bunschoten EP, Reesink HW, et al. Sexual transmission of hepatitis C virus. Lancet 1993;342:210-1.
3. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology 1997;26(3 Suppl 1):66S-70S.
4. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005;192:1880-9.
5. Hijikata M, Shimizu YK, Kato H, et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993;67:1953-8.
6. Alter HJ, Sanchez-Pescador R, Urdea M, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 1995;2:121-32
7. Katayama K, Kumagai J, Komiya Y, et al. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology 2004;47:57-64.
8. Busch MP, Murthy KK, Kleinman SH, et al. Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012;119:6326-34.
9. Damen M, Zaaijer HL, Cuypers HT, et al. Reliability of the third generation recombinant immunoblot assay for hepatitis C. Transfusion 1995;35:745-9.
10. Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005;45:994-1002.
11. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid amplification testing. N Engl J Med 2004;351:760-8.
12. Bernardin F, Stramer SL, Reherman B, et al. High levels of subgenomic HCV plasma RNA in immunosilent infections. Virology 2007;365:446-56.
13. Mohamoud YA, Mumtaz GR, Riome S, et al. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13:288.
14. El Ekyabi M, Laperche S, Moftah F, et al. The impact of different HCV blood screening technologies on the reduction of transfusion transmitted HCV infection risk in Egypt [Abstract 2C-S08-03]. Vox Sang 2009:9(Suppl 1);23.
15. Goubran H, Moftah F, El Ekiaby M, et al. Screening of blood donors by multiplex nucleic acid amplification technology reduces the risk of transmission of hepatitis B and C in Egypt [Abstract P071]. Vox Sang 2009:9(Suppl 1);90.
16. Grabarczyk P, Van Drimmelen H, Kopacz A, et al. Head to head comparison of two transcription mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1 in blood donors. Transfusion 2013;53:2512-24.
17. Bruhn R, Lelie PN, Custer B, et al.; International NAT Study Group. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions. Transfusion 2015;55:000-00.
18. Cable R, Lelie N, Bird A. Reduction of transfusion transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa. Vox Sang 2013;104:93-9.
19. Weusten J, Vermeulen M, Van Drimmelen H, et al. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011;51:203-15.
20. Kleinman SH, Lelie PN, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis V virus and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009;49:2454-89.
21. Saldanha J, Heath A, Lelie PN, et al. Calibration of HCV working reagents for NAT assays against the HCV international standard. The Collaborative Study Group. Vox Sang 2000;78:217-24.
22. Vermeulen M, Coleman C, Mitchel J, et al. Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk. Transfusion 2013;53:2384-98.
23. Lefrère JJ, Girot R, Lefrère F, et al. Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion. Transfusion 2004;44:343-8.
24. Operskalski EA, Mosley JW, Tobler LH, et al. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 2003;43:1433-41.
25. Moiz B, Moatter T, Shaik U, et al. Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan. Transfusion 2014;54:1652-9.
26. Carreno V. Occult HCV infection: a new form of hepatitis C. World J Gastroenterol 2006;12:6922-5.
27. Castillo I, Pardo M, Bartolomé J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004;189:7-14.
28. Lerat H, Hollinger FB. Hepatitis C virus (HCV) occult infection or occult HCV RNA detection? J Infect Dis 2004:189:3-6.
29. Feld JJ, Liang TJ. HCV persistence: cure is still a four letter word. Hepatology 2005;41:23-5.
30. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005;41:106-14.
31. Pham TN, Macparl SA, Mulrooney PM, et al. Hepatitis C persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004;78:5867-74.
32. Bernadin F, Tobler L, Walsh I, et al. Clearance of HCV-RNA from the PBMC of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008;47:1446-52.
33. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821-9.
34. Keck ZY, Li SH, Xia J, et al. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol 2008;83:6149-60.
35. Stramer SL, Dodd RY, Brodsky JP. The value of screening signal-to-cutoff ratios for hepatitis C virus antibody confirmation. Transfusion 2013;53:1497-500.
36. World Health Organization. Screening donated blood for transfusion transmissible infections: recommendations. WHO guideline. Geneva: WHO; 2009.